A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Trial Profile

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs MRX 34 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Liver cancer; Liver metastases; Lung cancer; Lymphoma; Myelodysplastic syndromes; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Mirna Therapeutics
  • Most Recent Events

    • 05 Dec 2016 Results (n=47) published in the Investigational New Drugs.
    • 10 Nov 2016 According to Mirna Therapeutics media release, FDA requested a final clinical study report along with risk-benefit summary with sufficient justification for the continued development of MRX34 to remove the clinical hold.
    • 11 Oct 2016 Results of next generation sequencing analysis presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top